Monopar Therapeutics Inc. (MNPR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 14.78M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 5.32M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -22.12M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.78M | (m) | $5.32M | $-22.12M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $11.75M | (m) | $5.18M | $-18.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $9.90M | $0.00 | $4.84M | $-16.70M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $15.89M | (m) | $4.01M | $-21.62M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $14.28M | (m) | $3.11M | $-19.11M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $13.68M | (m) | $2.17M | $-17.66M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $13.01M | $0.00 | $1.14M | $-16.16M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $4.12M | (m) | $1.34M | $-7.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $4.45M | (m) | $1.61M | $-7.49M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $4.91M | (m) | $1.75M | $-8.03M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $5.60M | (m) | $1.90M | $-8.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $6.67M | (m) | (m) | $-9.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $7.08M | (m) | (m) | $-10.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $7.57M | (m) | (m) | $-10.60M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $7.59M | (m) | (m) | $-10.54M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $7.47M | (m) | (m) | $-10.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $7.57M | (m) | (m) | $-10.36M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $6.96M | (m) | (m) | $-9.69M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $6.49M | (m) | (m) | $-9.13M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $6.14M | (m) | (m) | $-8.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $5.57M | (m) | (m) | $-7.90M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $4.93M | (m) | (m) | $-7.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $4.07M | (m) | (m) | $-6.51M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $3.02M | (m) | (m) | $-5.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $1.98M | (m) | (m) | $-4.58M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $1.48M | (m) | (m) | $-4.05M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $1.97M | $0.00 | (m) | $-4.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $1.91M | $0.00 | (m) | $-4.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $1.99M | $0.00 | (m) | $-4.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $2.15M | $0.00 | (m) | $-3.91M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $1.77M | $0.00 | (m) | $-3.40M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $1.56M | $0.00 | (m) | $-3.14M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $1.44M | $0.00 | (m) | $-17.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $1.26M | $0.00 | (m) | $-17.13M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $935.32K | $0.00 | (m) | $-16.60M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $280.36K | $0.00 | (m) | $-1.19M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |